Literature DB >> 16998756

Therapeutic options in autoimmune inflammatory myopathies (dermatomyositis, polymyositis, inclusion body myositis).

Dieter Pongratz1.   

Abstract

Polymyositis, dermatomyositis, and inclusion body myositis are idiopathic inflammatory myopathies of unknown etiology with autoimmune pathogenesis. For choosing an individual and efficient therapy, diagnostic assignment is an important factor. Therapeutic options in dermatomyositis and polymyositis include corticosteroids and immunosuppressives. Intravenous immunoglobulins are only needed in special cases. In inclusion body myositis, corticosteroids and immunosuppressives are not successful. At the moment intravenous immunoglobulins are the only therapeutic possibility.

Entities:  

Mesh:

Substances:

Year:  2006        PMID: 16998756     DOI: 10.1007/s00415-006-5010-2

Source DB:  PubMed          Journal:  J Neurol        ISSN: 0340-5354            Impact factor:   4.849


  3 in total

Review 1.  Mechanisms of action of intravenous immunoglobulin in inflammatory muscle disease.

Authors:  Adam Quick; Rup Tandan
Journal:  Curr Rheumatol Rep       Date:  2011-06       Impact factor: 4.592

2.  Crocin restores the balance of Th1/Th2 immune cell response in ConA-treated human lymphocytes.

Authors:  Hakimeh Abdi; Zahra Aganj; Hossein Hosseinzadeh; Fatemeh Mosaffa
Journal:  Pharmacol Rep       Date:  2022-03-16       Impact factor: 3.024

3.  Treatment of inclusion body myositis: is low-dose intravenous immunoglobulin the solution?

Authors:  Mike Recher; Ulrike Sahrbacher; Juliane Bremer; Börge Arndt; Urs Steiner; Adriano Fontana
Journal:  Rheumatol Int       Date:  2010-01-01       Impact factor: 2.631

  3 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.